The preliminary results of the NCT02674763 phase I trial, in R/R CD33+ AML, reported good tolerability and safety, with a response over 50% in patients receiving weekly administration and 35% in those treated every second week [115]. Here, CD33 is linked to acute myeloid leukemia.